Immunogenicity Analysis of the Recombinant <i>Plasmodium falciparum</i> Surface-Related Antigen in Mice
Jia-Li Yu,
Qing-Yang Liu,
Bo Yang,
Yi-Fan Sun,
Ya-Ju Wang,
Jian Jiang,
Bo Wang,
Yang Cheng,
Qiu-Bo Wang
Affiliations
Jia-Li Yu
Laboratory of Pathogen Infection and Immunity, Department of Public Health and Preventive Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
Qing-Yang Liu
Department of Clinical Laboratory, Wuxi 9th Affiliated Hospital of Soochow University (Wuxi 9th People’s Hospital), Wuxi 214000, China
Bo Yang
Laboratory of Pathogen Infection and Immunity, Department of Public Health and Preventive Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
Yi-Fan Sun
Laboratory of Pathogen Infection and Immunity, Department of Public Health and Preventive Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
Ya-Ju Wang
Wuxi Red Cross Blood Center, Wuxi 214000, China
Jian Jiang
Wuxi Red Cross Blood Center, Wuxi 214000, China
Bo Wang
Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China
Yang Cheng
Laboratory of Pathogen Infection and Immunity, Department of Public Health and Preventive Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
Qiu-Bo Wang
Department of Clinical Laboratory, Wuxi 9th Affiliated Hospital of Soochow University (Wuxi 9th People’s Hospital), Wuxi 214000, China
Plasmodium falciparum, mainly distributed in tropical and subtropical regions of the world, has received widespread attention owing to its severity. As a novel protein, P. falciparum surface-related antigen (PfSRA) has the structural and functional characteristics to be considered as a malaria vaccine candidate; however, limited information is available on its immunogenicity. Here, we expressed three fragments of recombinant PfSRA in an Escherichia coli system and further analyzed its immunogenicity. The results showed that rPfSRA-immunized mice produced specific antibodies with high endpoint titers (1:10,000 to 1:5,120,000) and affinity antibodies (i.e., rPfSRA-F1a (97.70%), rPfSRA-F2a (69.62%), and rPfSRA-F3a (91.87%)). In addition, the sera of immunized mice recognized both the native PfSRA and recombinant PfSRA, the rPfSRA antibodies inhibited the invasion of P. falciparum into the erythrocytes, and they were dose-dependent in vitro. This study confirmed PfSRA could be immunogenic, especially the F1a at the conserved region N-terminal and provided further support for it as a vaccine candidate against P.falciparum.
